Experts weigh genomic testing, treatment intensification, and radioligand sequencing in advanced prostate cancer care.
|Videos|May 23, 2011
Juanita Madison on Handling the Provenge Process
Author(s)Juanita Madison, MN, RN
Juanita Madison from the Seattle Cancer Care Alliance on Handling the Provenge Treatment Process
Advertisement
Lead researcher Juanita Madison, MN, RN, AOCN from the Seattle Cancer Care Alliance (SCCA) of a multidisciplinary study looking at Provenge discusses handling the treatment process. Using the Plan-Do-Study-Act quality-improvement model the multidisciplinary task-force devised, implemented, and revised a Provenge treatment strategy.
Advertisement
Related to this article
A dual antigen–targeted T-cell engager doublet produced durable PSA responses in late-line metastatic castration-resistant prostate cancer.
VET3-TGI produced responses in injected and non-injected lesions without dose-limiting toxicities in the phase 1/1b STEALTH-001 trial.
IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.
VGX-3100 met its composite primary end point in the phase 3 HPV-303CHN trial, supporting a nonsurgical treatment approach for HPV-16/18–associated cervical HSIL.
EVX-01 plus pembrolizumab generated sustained neoantigen-specific T-cell responses in advanced melanoma.
David VanderWeele, MD, PhD, reviews where lutetium Lu 177 vipivotide tetraxetan fits across metastatic prostate cancer, how to select and manage patients, and the new radionuclides, targeting molecules, and antigens under investigation.
Longer follow-up of CAPItello-281 showed capivasertib plus abiraterone extended survival in PTEN-deficient hormone-sensitive prostate cancer.
Advertisement
Advertisement
Trending on OncLive
1
Mo-Rez Responses Span B7-H4 Expression Levels in Platinum-Resistant Ovarian Cancer in BEHOLD-1 Biomarker Analysis
2
Genomic Testing, Toxicity, and Sequencing Shape Treatment Decisions in Advanced Prostate Cancer
3
FDA Approves Pimicotinib for Symptomatic TGCT
4
Dr Natsuhara on Treatment Advances and Research Considerations in TNBC
5